Literature DB >> 17429731

The microvascular thrombi of colonic tissue in ulcerative colitis.

Guobin He1, Qin Ouyang, Daiyun Chen, Fengyuan Li, Jingguo Zhou.   

Abstract

Mucosal microvascular thrombi in rectal biopsies were observed in some ulcerative colitis (UC). Heparin may be effective in steroid resistant UC in some studies, however, the new results of meta-analysis demonstrated a non-significant effect of heparin in controlled clinical trials, differing markedly from observational studies. The objective of this study was to identify colonic microvascular thrombi in larger cases with UC, and analyse its possible risk factors: age, gender, histologic score, extent of lesions and operation or biopsy specimens, and assess the significance of microvascular thrombosis in patients with UC. The microvascular thrombi were identified by immunohistochemical staining with anti-CD61 monoclonal antibody and Martius scarlet blue (MSB) staining in 40 colonic tissue samples of UC (31 biopsy specimens and nine operated cases) and 12 cases of normal colon tissue from operated colonic carcinoma. Logistic regression analysis was used to assess the relationship of age, gender, degree of histology, origin of the specimens, extent of lesions and microvascular thrombi examined. Microvascular thrombi were positive in 14 of 40 UC cases, and none in the controls. The presence of microvascular thrombi was related to operation specimens with odds ratio 11.667, P=0.0179, it might be also related to histologic score (OR=1.350) and extent of lesions (OR=1.619). These results suggest that microvascular thrombosis may be one of the important pathogenesis in some UC, and that the effect of anticoagulant treatment still needs to be assessed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429731     DOI: 10.1007/s10620-006-9158-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

2.  Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease.

Authors:  A A Van Bodegraven; H A Tuynman; M Schoorl; A M Kruishoop; P C Bartels
Journal:  Scand J Gastroenterol       Date:  1995-06       Impact factor: 2.423

3.  Inherited disorders of coagulation appear to protect against inflammatory bowel disease.

Authors:  N P Thompson; A J Wakefield; R E Pounder
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

4.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

Authors:  W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

5.  Paradoxical response to heparin in 10 patients with ulcerative colitis.

Authors:  P R Gaffney; C T Doyle; A Gaffney; J Hogan; D P Hayes; P Annis
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

6.  Mucosal capillary thrombi in rectal biopsies.

Authors:  A P Dhillon; A Anthony; R Sim; A J Wakefield; E A Sankey; M Hudson; M C Allison; R E Pounder
Journal:  Histopathology       Date:  1992-08       Impact factor: 5.087

7.  Platelets and anticoagulant capacity in patients with inflammatory bowel disease.

Authors:  Torben Bjerregaard Larsen; Jens Nederby Nielsen; Lisbeth Fredholm; Erik D Lund; Ivan Brandslund; Pia Munkholm; Henrik Hey
Journal:  Pathophysiol Haemost Thromb       Date:  2002 Mar-Apr

8.  Circulating D dimer in inflammatory bowel disease.

Authors:  L Biancone; F Scopinaro; M Maletta; G Monteleone; F Luzza; M Banci; P Mercantini; T Renda; F Pallone
Journal:  Ital J Gastroenterol       Date:  1994-04

9.  Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis.

Authors:  Anton A Vrij; Joop Rijken; Jan W J van Wersch; Reinhold W Stockbrügger
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Mar-Apr

10.  Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

Authors:  R C Evans; V S Wong; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

View more
  1 in total

1.  Papaverine adjuvant therapy for microcirculatory disturbance in severe ulcerative colitis complicated with CMV infection: a case report.

Authors:  Yu Tian; Yue Zheng; Jinpei Dong; Jixin Zhang; Huahong Wang
Journal:  Clin J Gastroenterol       Date:  2019-04-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.